Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat 2 Small-Cap Biotechs That Could Reward Patient InvestorsBy Chris Markoch. Article Posted: 12/12/2025. 
Article Highlights - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investing and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, which means they typically have no commercially available drugs or therapeutics. That also means negative earnings (they are not yet profitable) and little to no revenue. Success frequently hinges on the outcome of a single clinical-stage program. Just like Microsoft and Adobe rode the software wave in Web 1.0, RAD Intel is riding the AI software wave in 2025. Their product helps brands instantly find the right audience and message using AI – solving the #1 waste in marketing: misfired ad spend.
Already trusted by a who's-who of Fortune 1000 brands and leading global agencies – with recurring seven-figure partnerships in place. With a Nasdaq ticker reserved, $RADI, it's early – but very real. $0.85 Won't Last – Secure Your Shares Now. Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies usually gain the analyst coverage that attracts institutional investment. Still, getting into one of these medical stocks early and seeing it succeed can produce very large returns. In an instant, investors could realize 3x, 5x, or even 10x gains. Others may never pan out. For that reason, many investors interested in penny stocks spread a lump sum across a number of biotech names. If it is a numbers game, diversification can be a sensible strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is significant. The company is also developing a non-invasive blood-based screening test for early pancreatic cancer and reported positive topline results in October. Commercial availability for that test, however, remains years away. That said, risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, overall revenue remains minimal. Those concerns are reflected in the company’s Sept. 26 SEC filing, which includes “Going Concern” language. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that appears sufficient to keep the MYNZ share price above $1 and avoid a delisting notice. The company is effectively racing to generate enough revenue to change its financial outlook. If it succeeds, even a small position could deliver a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that pursues a potentially disruptive antiviral approach—but it also carries the financial risk speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on additional capital to advance programs. The company reported limited cash on hand in recent filings, and investors should anticipate the possibility of future dilution. Still, if one of its candidates advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
